Is PALVELLA THERAPEUTICS, INC. (PVLA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 4.4% / 30% | 0.1% / 30% | N/A | ✓ HALAL |
| DJIM | 0.0% / 33% | 4.4% / 33% | 0.1% / 33% | N/A | ✓ HALAL |
| MSCI | 0.0% / 33% | 94.8% / 33% | 2.6% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 4.4% / 33% | 0.1% / 33% | N/A | ✓ HALAL |
| FTSE | 0.0% / 33% | 94.8% / 33% | 2.6% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -301.2% | |
| Return on Assets (ROA) | -47.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$11M |
| Free Cash Flow | -$11M |
| Debt-to-Equity | 41.4 |
| Current Ratio | 6.5 |
| Total Assets | $88M |
Price & Trading
| Last Close | $117.61 |
| 50-Day MA | $104.97 |
| 200-Day MA | $73.68 |
| Avg Volume | 307K |
|
52-Week Range
$18.23
| |
About PALVELLA THERAPEUTICS, INC. (PVLA)
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is PALVELLA THERAPEUTICS, INC. (PVLA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), PALVELLA THERAPEUTICS, INC. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is PALVELLA THERAPEUTICS, INC.'s debt ratio?
PALVELLA THERAPEUTICS, INC.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are PALVELLA THERAPEUTICS, INC.'s key financial metrics?
PALVELLA THERAPEUTICS, INC. has a market capitalization of $1.6B. Return on equity stands at -301.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.